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Background: The primary endpoint of head-to-head comparisons of coronary drug-
eluting stents is traditionally assessed after 9-12 months. However, the optimal time
point for assessment of the primary endpoint remains unsettled.
Methods: We randomised 2,332 patients to zotarolimus-eluting Endeavor stent
(E-ZES; n¼1,162) or sirolimus-eluting Cypher stent (C-SES; n¼1,170) implanta-
tion. Endpoints included a composite of cardiac death, myocardial infarction or target
vessel revascularization (MACE) and deﬁnite stent thrombosis. This trial is registered
with ClinicalTrials.gov, number NCT00660478.
Results: At 5-year follow-up, MACE rates were similar in patients treated with E-ZES
and C-SES (197 [17%] vs. 182 [16%]; odds ratio [OR] ¼1.10, 95% conﬁdence
intervals [CI]: 0.88-1.37; p¼0.40). This ﬁnding reﬂected oppositely directed MACE
rates within year 1 (93 [8%] vs. 46 [4%]; OR¼2.13, 95% CI: 1.48-3.07; p<0.001) and
year >1 through 5 (104 [10%] vs. 136 [12%]; OR¼0.78, 95% CI: 0.59-1.02;
p¼0.071). Deﬁnite stent thrombosis was more frequent after E-ZES than C-SES
implantation at 1-year (13 [1.1%] vs. 4 [0.3%]; OR¼3.34, 95% CI: 1.08-10.3;
p¼0.036) while the opposite was found for year >1 through 5 (1 [0.1%] vs. 21
[1.8%]; OR¼0.05, 95% CI: 0.01-0.35; p¼0.003). In the E-ZES and C-SES group,
26 of 88 (30%) and 54 of 70 (77%) of target lesion revascularisations occurred
between 1 and 5 years, respectively.
Conclusions: A traditional 1-year primary endpoint is insufﬁcient to predict 5-year
clinical outcome in patients treated with coronary drug-eluting stent implantation.
Long-term clinical data from routine clinical care populations should be a prerequisite
for unrestricted use of new coronary drug-eluting stents.
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Background: Longterm results with drug eluting stents are important considering late
differences in stent thrombosis, neo-athererosclerosis and catch-up phenomena that
has been observed in several stent studies. Furthermore, little is known of longterm
results with the everolimus-eluting stent, speciﬁcally in comparison with the
paclitaxel-eluting stent.
Methods: 1800 consecutive patients scheduled for PCI have been randomized to
receive a Xience V (EES) or Taxus Liberte (PES) stent. Inclusion criteria were:
patients eligible for PCI and a life expectancy of > 5 years. Major exclusion criteria
were: no expected dual platelet therapy for 12 months, cardiac shock at presentation,
planned major surgery within 1 month. The primary end point is the composite of: all
death, non fatal myocardial infarction (MI) and target vessel revascularization (TVR)
at 12 months. The secondary end points are: A) The combined endpoint of cardiac
death, MI, ischemic driven target lesion revascularization rate at 12 months follow-up.
B) the combined endpoint of all death, MI and TVR rate at 3 and 5 years follow-up.
All patients will be monitored up to 60 months follow-up. Adjudication of events and
core lab analysis of unscheduled angios is done independently by Cardialysis, Rot-
terdam, The Netherlands. A post-hoc SYNTAX score analysis will be done in the
subgroup of multivessel and/or left main treatment.
Results: No differences in patient baseline characteristics and lesion characteristics
were present between both groups. Clinical presentation was similar in both groups
(EES versus PES: Stable angina 40 vs 41%, Unstable angina 12 vs 12%, Non STEMI
22 vs 24%, STEMI 27 vs 23%, respectively). Overall 1.4 lesions per patient have been
treated with an average of 1.6 stents per lesion and an average 2.3 stents per patient,
reﬂecting real world situation with pronounced vessel disease patients. The adjudi-
cation of events between 3 and 5 year follow-up is in progress and will be ready ﬁrst
week September 2013.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: COMPARE is the ﬁrst trial that will show adjudicated longterm data of
EES and in comparison to PES. These 5 year results may have clinical implications,
speciﬁcally for those patients with high SYNTAX scores.
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Background: US guidelines currently recommend 12 months of uninterrupted DAPT
after implantation of DES. Prolonged and more powerful DAPT regimens have
offered beneﬁt by reducing VLST, but at the cost of increased risk of bleeding. There
is an emerging need for new stents that are less dependent on prolonged DAPT. The
BioFreedom stent (BFD) releases Biolimus A9, without using a polymer or binder.
Based on an animal model, 98% of the drug diffuses to the vessel wall within 1 month,
leaving a BMS in place. It is reasonable therefore to consider that the stent offers
a potential safety advantage and a reduced need for prolonged DAPT compared to
a polymer based DES. This First-In-Man trial aims to demonstrate the safety and
effectiveness of theBFDcompared to the Taxus Liberté paclitaxel-eluting stent (PES).
Methods: The BioFreedom FIM is a prospective, multi-center, randomized trial. 182
patients were enrolled and randomized to BFD Standard Dose (SD, 15.6 mg/mm), or
BFD Low Dose (LD, 7.8 mg/mm), or Taxus Liberté DES. The primary endpoint was
in-stent Late Loss (LL) at 12 months. The main secondary endpoints are IVUS
neointimal volume at 4 & 12 months; MACE (death, MI, emergent bypass or
clinically-driven TLR) and ST rates (ARC deﬁned) at 30 days, 4 and 12 months, and
then yearly up to 5 years.
Results: The in-stent LL was non inferior in BFD SD (p non-inferiority ¼ 0.001) and
trended towards superiority with medians of 0.17mm [0.09, 0.39] vs. 0.35mm [0.22,
0.57] compared to PES (p sup¼0.11) at 12 months. At 3 years, the clinical FU was
96%. The BFD SD and PES showed similar rates of MACE (BFD SD 11.9% vs. PES
10.0%) with no deﬁnite/probable ST in any group. Interestingly, at 2 years, there was
a signiﬁcant difference in adherence to DAPT between the groups (BFD SD 5.2% vs.
PES 19% p¼0.025) which disappeared at 3 years.
Conclusions: The safety and efﬁcacy of the polymer free BioFreedom has been
shown out to 3 years. An ongoing trial is studying the possibility of using this stent in
patients with high bleeding risk, unable to tolerate a prolonged course of DAPT. The
BioFreedom FIM 4-year follow-up will be reported for the 1st time during this
presentation.
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Background: A drug-eluting stent consists of 3 components of equal importance:
a metallic platform, a polymer and a drug, all inﬂuencing acute and long term results
both in safety and efﬁcacy. The PLATINUM PLUS trial was designed to compare the
PROMUS Element stent (Boston Scientiﬁc; Natick, MA, US) to the XIENCE
PRIME (Abbot Vascular; Santa Clara, CA, US). These two stents have the same
polymers [poly (n butyl methacrylate) (PBMA) and poly (vinylidene ﬂuoride co
hexaﬂuoropro-pylene) (PVDF-HFP)] and drug (Everolimus) but different platforms
(platinum-chromium for the PROMUS Element, cobalt chromium for the XIENCE
PRIME) and distinct stent designs.
Methods: The trial was designed as a non-inferiority single blind randomized 2:1 trial
(PROMUS Element: P / XIENCE PRIME: X) and recruited from October 2010 to
February 2012 2979 consecutive, all-comer patients in 48 European centers. The
primary endpoint was Target Vessel Failure (TVF: ischemia-driven target vessel
revascularization (TVR), any MI or cardiac death related to the target vessel) at 1 year.acts/ORAL/Bare Metal and Drug-Eluting Stents B5
